Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients

Gynecologic Oncology
Gabriella FerrandinaCristiano Ferlini

Abstract

The aim of the study was to investigate the potential clinical relevance of immunohistochemically assessed RON expression in a large, single institution series of primary untreated advanced ovarian cancer patients. Immunohistochemical analysis was performed by using the polyclonal rabbit anti-RON-beta antibody (C-20, clone sc-322, Santa Cruz, California). Results were expressed as the total proportion of immunostained tumor cells (RON positivity), or the percentage of cells showing strong staining of RON expression (H-RON positivity). In the overall series RON positive immunoreaction was observed in 103/141 cases, while H-Ron positivity was detected in 577141 (40.4%) cases. No association between RON and H-RON expression with response to first-line treatment was documented. During the follow up period, progression and death of disease were observed in 111 (78.7%) and 76 (53.9%) cases, respectively. Cases with strong H-RON expression has a shorter overall survival (median=35 months) than cases with low RON levels (median=59 months) (X(2)=-2.1, p value=0.032). In multivariate analysis, only platinum resistance, and extent of residual tumor retained an independent negative prognostic role for OS, with the percentages of H-RON posi...Continue Reading

References

Oct 23, 1997·International Journal of Cancer. Journal International Du Cancer·A N CorpsS K Smith
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Aug 14, 2003·Experimental Cell Research·Piera MaggioraMaria Flavia Di Renzo
Mar 25, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wen-Ying LeeHow-Ran Guo
Apr 14, 2005·Annals of Surgical Oncology·E Ramsay CampLee M Ellis
Jul 25, 2006·Nature Reviews. Cancer·Carla Boccaccio, Paolo M Comoglio
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
May 2, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FerrandinaG Scambia

❮ Previous
Next ❯

Citations

May 23, 2015·Oncology Reports·Sebastian MayerElmar Stickeler
Jul 22, 2014·Critical Reviews in Biochemistry and Molecular Biology·Deepak Sharma, Eckhard Jankowsky
Jul 28, 2012·Expert Opinion on Therapeutic Targets·Nancy M Benight, Susan E Waltz
Dec 3, 2014·American Journal of Obstetrics and Gynecology·Ernst LengyelIris L Romero
Jun 26, 2013·Nature Reviews. Cancer·Hang-Ping YaoMing-Hai Wang
Nov 27, 2016·Archives of Gynecology and Obstetrics·Ping XuXinmei Zhang
Dec 22, 2020·Biochimica Et Biophysica Acta. Reviews on Cancer·Thomas ChabotFabrice Fleury
Sep 26, 2020·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Sheng-Lin WangJian-Hua Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.